Cell line · CVCL_1681
SCC-15
Cancer cell line, Homo sapiens. Tongue squamous cell carcinoma. 36 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. SCC-15. Cell lines, record CVCL_1681. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1681
On this page
Cell line
As Cellosaurus gives it.
- Name
- SCC-15
- Accession
- CVCL_1681
- RRID
- RRID:CVCL_1681
- Synonyms
- SCC 15, SCC15
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 55Y
- Category
- Cancer cell line
- Diseases
- Tongue squamous cell carcinoma (NCIt C4648); Squamous cell carcinoma of the oral tongue (ORDO Orphanet_457252)
- Derived from
- Oral cavity, tongue (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers36
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Dual targeting of ACSS2 and ACLY by a novel inhibitor S8588 suppresses oncogenic lipogenesis and overcomes metabolic compensation in oral squamous cell carcinoma. | Int J Oral Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. | J Transl Int Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. | Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Lingual Denervation Improves the Efficacy of Anti-PD-1 Immunotherapy in Oral Squamous Cell Carcinomas by Downregulating TGFβ Signaling. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ORAOV1, CCND1, and MIR548K Are the Driver Oncogenes of the 11q13 Amplicon in Squamous Cell Carcinoma. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The deleted in oral cancer (DOC1 aka CDK2AP1) tumor suppressor gene is downregulated in oral squamous cell carcinoma by multiple microRNAs. | Cell Death Dis | 2023 | Its Methods give the RRID and name the line | PubMed | |
| F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
1 to 10 of 36
See all 36 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | SCC15/R1 | CVCL_B5MP | Cell lines | |
| Derived from it | SCC15/R2 | CVCL_B5MQ | Cell lines | |
| Derived from it | SCC15/R3 | CVCL_B5MR | Cell lines | |
| Derived from it | SCC15/R4 | CVCL_B5MS | Cell lines |
Cell banks2
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1623 | ATCC | |
| BCRJ | 0218 | Discontinued | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1681
GET https://conductscience.org/api/cell-lines/v1/CVCL_1681/papers?page=2